Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort studyNeena S. Abraham(Mayo Clinic in Florida), Nilay D. Shah(Mayo Clinic in Florida)BMJApril 24, 201510.1136/bmj.h1857Cited by 345SaveCiteExport RISWatch citationsRelated PapersACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use|Circulation|2008|845